The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA), met with Presidential Candidate Giorgos Lillikas, within the framework of its meetings with the presidential candidates.
“We had a very substantive dialogue with Mr. Lillikas and we had the opportunity to submit our proposals aiming to improve the healthcare system in Cyprus and make innovative medicines accessible in the best interest of the patients. Among others, we discussed the necessity for the creation of the mechanisms that will allow individual patients access to innovation,” stated Ms. Jacqueline Anastassiades, KEFEA President.
KEFEA and Mr. Lillikas also exchanged views on issues regarding the implementation of the EU Transparency Directive in Cyprus, support mechanisms for fair pricing, improvement of the current tender procedures for the purchase of medicines, support for accelerated and uncompromised implementation of the GESY, as well as the fair and balanced promotion of Pharmaceuticals by all parties involved.
Finally, KEFEA, representing the innovative pharmaceutical industry in Cyprus and a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), assured Mr. Lillikas, that it is committed to providing any support required on a European level in order to help the Cypriot authorities in their efforts to create a better National Health System.
Presidential candidate Giorgos Lillikas with KEFEA delegation consisting of: Jacqueline Anastassiades, President, Daan Gijbels, Vice President and Joanna Kozakou, member.
Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA)
The Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) was founded in 2006 as the representative body of multinational pharmaceutical companies in Cyprus. Its members are GSK, Lilly, MSD, Novartis, Pfizer, Sanofi, Janssen and Amgen Hellas altogether employing more than 300 people in Cyprus. It is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). KEFEA’s mission is to
provide Cypriots with quality healthcare and access to new medicines. Its objectives are to ensure uninterrupted access to medicines at reasonable prices in the Cyprus market, given the acknowledgement of budgetary constraints, provide scientific educational information on diseases and treatments to healthcare providers, ensure that European objectives regarding high healthcare standards are implemented in the Cyprus market, and comply with a common code of ethical practice.